Thoracic Malignancies

European Respiratory Society Monograph, Vol. 44. 2009

ISBN: 978-1-904097-68-6

DOI: 10.1183/1025448x.ERM4409

Lung cancer is estimated to be the fifth most common cause of death in the world and the most commonly diagnosed cancer. This book covers the huge advances that have been made in understanding the biology of lung cancer, the improvements in diagnostic staging and the introduction of new molecularly targeted therapies. An essential reference guide for respiratory physicians dealing with all aspects of thoracic malignancies.

The Guest Editors Eur Respir Mon; 2009: 44: vii
Preface Eur Respir Mon; 2009: 44: viii
Introduction Eur Respir Mon; 2009: 44: ix
Lung cancer: oncogenesis and prevention N. van Zandwijk Eur Respir Mon; 2009: 44: 1–14
Pathology and immunohistochemistry of lung cancer E. Brambilla, S. Lantuejoul Eur Respir Mon; 2009: 44: 15–35
Pre-invasive diseases of the lung D.T. Merrick, F.R. Hirsch Eur Respir Mon; 2009: 44: 36–56
Screening for lung cancer D.E. Midthun, J.R. Jett Eur Respir Mon; 2009: 44: 57–70
Symptoms and signs of lung cancer N. Navani, S.G. Spiro Eur Respir Mon; 2009: 44: 71–87
The biology of lung cancer M.H. Lawson, T. Eisen Eur Respir Mon; 2009: 44: 88–105
Radiology of lung cancer M.N. Taylor, P. Shaw Eur Respir Mon; 2009: 44: 106–135
Diagnostic endoscopic investigations in lung cancer N. Navani, S.M. Janes Eur Respir Mon; 2009: 44: 136–149
Staging of lung cancer J-P. Sculier Eur Respir Mon; 2009: 44: 150–168
Functional evaluation for treatment C.F.N. Koegelenberg, D. Plekker, C.T. Bolliger Eur Respir Mon; 2009: 44: 169–186
The surgical treatment of lung cancer E. Potton, S.M. Janes, S.G. Spiro Eur Respir Mon; 2009: 44: 187–206
Radiotherapy in the treatment of nonsmall cell lung cancer M.Q.F. Hatton, J. Martin Eur Respir Mon; 2009: 44: 207–243
Neoadjuvant and adjuvant treatment for operable nonsmall cell lung cancer M. Mukesh, D. Gilligan Eur Respir Mon; 2009: 44: 244–259
Management of locally advanced nonsmall cell lung cancer M. Edelmann, R.M. Huber Eur Respir Mon; 2009: 44: 260–270
Chemotherapy in advanced nonsmall cell lung cancer E. Quoix Eur Respir Mon; 2009: 44: 271–283
Targeted therapy in nonsmall cell lung cancer D.F. Heigener, M. Reck, U. Gatzemeier Eur Respir Mon; 2009: 44: 284–298
Treatment of limited disease-small cell lung cancer D. De Ruysscher, C. Pöttgen, H.J.M. Groen, S.M. Bentzen Eur Respir Mon; 2009: 44: 299–309
Management of extensive disease-small cell lung cancer P.E. Postmus, E.F. Smit Eur Respir Mon; 2009: 44: 310–317
Malignant pleural disease in primary lung cancer E. Mishra, H.E. Davies, Y.C.G. Lee Eur Respir Mon; 2009: 44: 318–335
Endobronchial management of central cancers F.J.F. Herth Eur Respir Mon; 2009: 44: 336–348
Epidemiology of lung cancer and mesothelioma J.M. Samet, A.J. Alberg, J.G. Ford Eur Respir Mon; 2009: 44: 349–391
Diagnosis and staging of mesothelioma A. Scherpereel Eur Respir Mon; 2009: 44: 392–406
Surgery and multimodality treatment for malignant pleural mesothelioma W. Weder, I. Opitz, R. Stahel Eur Respir Mon; 2009: 44: 407–418
Systemic treatment of malignant mesothelioma R.M. Rudd Eur Respir Mon; 2009: 44: 419–434
Statements of interest Eur Respir Mon; 2009: 44: 435–437